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Betamethasone valerate and beclomethasone dipropionate aerosols have been shown to be effective in the treatment of asthma while being devoid of the side effects of systemic steroids. They have not previously been used in patients with 'irreversible' airways obstruction associated with chronic bronchitis, although a short report on the use of triamcinolone acetonide aerosol has indicated that some will respond to this route of corticosteroid administration (Matlin, 1976) . Oral corticosteroids, however, have been used in several studies with some investigations claiming objective improvement (Franklin et al., 1958; Clifton and Stuart-Harris, 1962; Beerel et al., 1963; Freedman, 1963) , some, subjective improvement only (Cullen and Reidt, 1960; Beerel and Vance, 1971) , and others no benefit (Morgan and Rusche, 1964; Oppenheimer et al., 1968; Evans et al., 1974 (Cotes, 1975) and/or FEV1.0/vital capacity ratio less than 0 6). We excluded patients with a present or past diagnosis of asthma and patients with a history of wheezing or breathlessness which was episodic or seasonal. Outpatients were referred specifically for assessment and possible entry to the study by their general practitioners. Inpatients were admitted if they suffered an exacerbation of their chronic bronchitis or if they were severely limited by chronic respiratory symptoms as outpatients.
DRUGS
Outpatients were given three packs, each containing material for 10 days' treatment, which was taken on a single-blind basis. Each pack contained a pressurised aerosol, two puffs to be inhaled four times a day and tablets, one to be taken three times a day. Treatment 1 comprised placebo aerosol (propellants only) and placebo tablets (lactose), treatment 2 comprised active aerosol (betamethasone valerate, 100 ,ug per puff) and placebo tablets, and treatment 3 comprised placebo aerosol and prednisone tablets (10 mg per tablet). One patient was given 10 mg prednisone/day and another 20 mg/ day because of coexisting medical problems.
Inpatients were given a placebo aerosol for an initial 7-10 days. When FEV1.0 and peak expiratory flow rate (PEFR) readings were judged to be stable over a three-day period, the aerosol was changed, without the patient's knowledge, to one containing betamethasone valerate (800 ug/day). After a further 7-10 days, the aerosol was discontinued, and the patients were given prednisolone, 30 mg/day for one week. (FVC) were measured using a dry spirometer (Vitalograph) and also peak expiratory flow rate (PEFR) using the Wright peak-flow meter. Skin (prick) tests to 13 common allergens were carried out, a wheal >3 mm being regarded as positive. Sputum was examined for eosinophils by wet eosin or Leishman's stain and recorded as positive if more than occasional such cells were seen. Blood eosinophilia was recorded if more than 500 cells were seen on a differential count of a stained smear. Additional observations on the inpatients included response to isoprenaline (800 ,ug from a pressurised aerosol), grading of right ventricular hypertrophy from ECG (Goodwin and Abdin, 1959) , and, in most cases, measurement of arterial Pco2 (Paco2) within a few days of admission.
FOLLOW-UP
Throughout the trial outpatients filled in a diary card of symptoms and twice daily measurements with an Airflometer (AFM), a portable device for quantitating airways obstruction (Friedman and Walker, 1975) . Inpatients had twice daily measurements of FEVY.o, FVC, and PEFR before and after the inhalation of 800 ,ug isoprenaline. In addition, daily sputum volume was measured. In four patients sputum collections were unsatisfactory in the third week of the trial.
Results
Five patients differed from the rest by virtue of an unequivocal increase in FEV1.0 or AFM readings on steroids. In addition, a sixth patient had a small but statistically significant improvement in FEVY.0.
Of the patients who responded to steroids, the inpatients did almost as well on inhaled steroid, but the outpatient responders had much better responses to oral prednisone (Fig. 1) . A low initial FEV1.0 did not prevent a response to the steroid aerosol. The outpatient responders improved more during the placebo period than did the inpatients. Three of the six responders had blood eosinophilia 'compared with three of 30 non-responders (P<005, by x2 analysis). Sputum eosinophilia was present in two of the four specimens obtained from responders. Personal or family history of allergy and positive skin tests did not help to predict a response. The only other feature which came close to separating the steroid-responders from the others was that of variability of ventilatory capacity, as assessed by AFM readings or FEVY.0 measured during the placebo period. Thus, in the outpatients, of the three with the largest measured variation in AFM units, two were steroid responders; in the inpatient group, of the six with S. M. Harding and S. Freedman the largest variation in FEV1.0, three were steroid responders (Fig. 2) . Patient 6 could not be distinguished from the group as a whole. Correlation between the measured variation in AFM or FEV,.0 and the subjective impression of variability of symptoms was poor (Fig. 2) . Analysis of the answers to the questionnaire'
'Full details of patients and results available from S. M. Harding failed to reveal a pattern of symptoms which would discriminate between steroid-responders and the others. All the responders excepting one had chest radiographs which were within normal limits. Overinflation (Hodson et al., 1974) was not a feature and occurred in 13 of the 30 nonresponders. The additional information which was available only for inpatients, ie, response to isoprenaline, sputum volume, grade of right ventricular hypertrophy, and Paco2, was also unhelpful. The responders did not demonstrate greater reversibility to isoprenaline during the placebo period than the non-responders and neither did oral or inhaled steroid produce an increase in reversibility. The effect of steroids, oral or aerosol, on sputum volume was variable. There was no correlation between changes in FEVY.0 and sputum volume, and in one patient a large daily sputum volume did not prevent a good response to inhaled steroids.
Discussion
Five of 36 patients who had apparently irreversible airways obstruction had a clear measured improvement in ventilatory capacity after treatment with corticosteroids while one other patient had a smaller increase. Three had blood eosinophilia while variability in ventilatory capacity, as judged by a large standard error of the mean of AFM or FEV1.0 readings during the placebo period, was a feature of the five clear responders. This raises the question whether these patients really had asthma.
Similarly, other studies have shown that steroidresponders frequently have features suggestive of asthma. Freedman (1963) studied 26 patients with chronic airways obstruction and found that the six who showed an appreciable response to steroids had personal or family histories of allergy. Beerel et al. (1963) found that two of their 10 patients with 'stable pulmonary emphysema' responded to steroids-both had asthmatic symptoms starting before the age of 20 and personal histories of allergy. More recently, Brewis et al. (1974) and Matlin (1976) have found response to steroids to be associated with blood eosinophilia. However, Clifton and Stuart-Harris (1962) found a 'striking' improvement in forced expiratory tests after one week on steroids in seven of their 28 patients, and, of these, only two were thought to have 'asthmatic bronchitis'; the remaining five were indistinguishable clinically from those with typical chronic bronchitis who did not respond to steroids. Oppenheimer et al. (1968) used criteria similar to ours for selection of patients and concluded that none of their 26 patients had a good response to steroids, although in fact four patients had a greater than 20% improvement in FEVV1.0 on prednisone. It is impossible to tell from their data whether these four were included in those who had positive skin tests or blood or sputum eosinophilia. Of the remaining trials-including that of Cullen and Reidt (1960) , who deliberately selected patients with 'bronchospasm' and included five patients with a possible diagnosis of allergic asthma-none has demonstrated objective evidence of improvement with steroids.
It is thus still not clear which patients with chronic bronchitis will respond to steroids, although it appears that the presence of features usually associated with asthma indicate a possible response. The report of the Working Group on the Definition of Asthma (1971) concluded that asthma could not be defined separately from chronic obstructive bronchitis and recommended that authors provide as much detailed information as possible about their patients. We would agree with this report since we were not able usefully to separate 'responders' from 'non-responders'.
Therefore the concept still stands that every patient with 'irreversible' airways obstruction, whatever features present on assessment, deserves a trial of steroids. A suggested protocol for such a trial is as follows: Firstly, there should be objective assessment of ventilatory capacity, preferably by several measurements rather than a single one at the end of the treatment period. Secondly, there should be a placebo period either before or after the active treatment. Thirdly, the treatment period should last at least 10 days. Fourthly, the dose should be adequate. A steroid aerosol can be substituted for prednisolone where systemic steroids are contraindicated, but, in general, especially for outpatients, oral steroids will be found to give a more definitive response. A steroid aerosol could then be substituted if there is a response and careful supervision of the technique of aerosol administration carried out. 
